Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients
Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
This is a single-arm Phase I/II study of sorafenib and bortezomib with dose optimization in
initial patients. The initial patients on the dose-finding portion of this study will be
enrolled through a single institution. Following establishment of the Phase II dose the study
will open enrollment throughout the Sarah Cannon Research Institute (SCRI) Oncology Research
Consortium.
The purpose of this study is to develop the combination of bortezomib (which is proven to be
clinically active in patients with multiple myeloma) with sorafenib (a potent inhibitor of
angiogenesis). This regimen will be developed in a schedule that is convenient for patients,
and that is as minimally toxic to patients as possible.